JP2008519813A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008519813A5 JP2008519813A5 JP2007540709A JP2007540709A JP2008519813A5 JP 2008519813 A5 JP2008519813 A5 JP 2008519813A5 JP 2007540709 A JP2007540709 A JP 2007540709A JP 2007540709 A JP2007540709 A JP 2007540709A JP 2008519813 A5 JP2008519813 A5 JP 2008519813A5
- Authority
- JP
- Japan
- Prior art keywords
- endogenous target
- ligand
- target compound
- use according
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 41
- 239000003446 ligand Substances 0.000 claims 38
- 230000027455 binding Effects 0.000 claims 30
- 230000000694 effects Effects 0.000 claims 13
- 238000001727 in vivo Methods 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 6
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 6
- 102000003675 cytokine receptors Human genes 0.000 claims 4
- 108010057085 cytokine receptors Proteins 0.000 claims 4
- 238000012377 drug delivery Methods 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 3
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 3
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 239000007921 spray Substances 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 108010001831 LDL receptors Proteins 0.000 claims 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 2
- 102000007562 Serum Albumin Human genes 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000037317 transdermal delivery Effects 0.000 claims 2
- 229940126062 Compound A Drugs 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000034423 Delivery Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 102000007238 Transferrin Receptors Human genes 0.000 claims 1
- 108010033576 Transferrin Receptors Proteins 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003405 delayed action preparation Substances 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229940071648 metered dose inhaler Drugs 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 230000009677 vaginal delivery Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/985,847 US20060002935A1 (en) | 2002-06-28 | 2004-11-10 | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| PCT/GB2005/004319 WO2006051288A2 (en) | 2004-11-10 | 2005-11-10 | Ligands that enhance endogenous compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008519813A JP2008519813A (ja) | 2008-06-12 |
| JP2008519813A5 true JP2008519813A5 (enExample) | 2008-12-04 |
Family
ID=36282598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007540709A Pending JP2008519813A (ja) | 2004-11-10 | 2005-11-10 | 内因性化合物を増強するリガンド |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP2420251A3 (enExample) |
| JP (1) | JP2008519813A (enExample) |
| KR (2) | KR20070084069A (enExample) |
| CN (2) | CN101724071A (enExample) |
| AU (1) | AU2005303584A1 (enExample) |
| BR (1) | BRPI0517569A (enExample) |
| CA (1) | CA2587206A1 (enExample) |
| MA (2) | MA29427B1 (enExample) |
| NO (2) | NO20071788L (enExample) |
| RU (2) | RU2401842C2 (enExample) |
| WO (1) | WO2006051288A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| BRPI0511755A (pt) | 2004-06-01 | 2008-01-02 | Domantis Ltd | composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização |
| EP1802333A2 (en) | 2004-09-13 | 2007-07-04 | Arrowsmith Technologies LLP | Antibody buffering of a ligand in vivo |
| RU2007119989A (ru) * | 2004-12-02 | 2009-01-10 | Домантис Лимитед (Gb) | Композиции, слитые конструкции и конъюгаты plad домена |
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| US12203113B2 (en) | 2009-07-09 | 2025-01-21 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| CN102010473A (zh) * | 2010-11-10 | 2011-04-13 | 曹鹏 | 重组胃泌酸调节素融合蛋白及其制备和应用 |
| EP2726511B1 (en) | 2011-07-01 | 2019-08-07 | NGM Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| NZ730271A (en) * | 2012-03-16 | 2022-09-30 | Regeneron Pharma | Non-human animals expressing ph-sensitive immunoglobulin sequences |
| PE20142405A1 (es) | 2012-04-19 | 2015-01-25 | Opko Biolog Ltd | Variantes de oxintomodulina de accion prolongada y metodos de produccion de las mismas |
| EP2922867B1 (en) | 2012-11-20 | 2021-07-21 | OPKO Biologics Ltd. | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides |
| EP2925775B1 (en) | 2012-11-28 | 2020-09-16 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| KR102724421B1 (ko) | 2012-12-27 | 2024-10-30 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법 |
| RU2560699C2 (ru) * | 2013-08-02 | 2015-08-20 | федеральное государственное автономное образовательное учреждение высшего профессионального образования "Национальный исследовательский ядерный университет МИФИ" (НИЯУ МИФИ) | Способ создания наноразмерной диагностической метки на основе конъюгатов наночастиц и однодоменных антител |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| TWI710570B (zh) | 2014-07-30 | 2020-11-21 | 美商Ｎｇｍ生物製藥公司 | 用於治療代謝異常之組成物及方法 |
| CN107108711B (zh) | 2014-10-23 | 2021-11-23 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
| AP2017009828A0 (en) | 2014-10-31 | 2017-03-31 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
| PH12017501089B1 (en) | 2014-12-10 | 2022-06-22 | Opko Biologics Ltd | Methods of producing long acting ctp-modified growth hormone polypeptides |
| AU2016280867B2 (en) | 2015-06-19 | 2020-02-27 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| JP6728352B2 (ja) | 2015-11-09 | 2020-07-22 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 胆汁酸に関係した障害の治療方法 |
| KR102618424B1 (ko) | 2016-07-11 | 2023-12-26 | 옵코 바이오로직스 리미티드 | 지속성 응고 인자 vii 및 그 제조 방법 |
| CN110128536A (zh) * | 2018-02-02 | 2019-08-16 | 暨南大学 | 抗肿瘤干细胞标志蛋白cd133的单域抗体及其应用 |
| CN118702818A (zh) | 2018-11-01 | 2024-09-27 | 生物发明国际公司 | 新型拮抗性抗tnfr2抗体分子 |
| CN109468294A (zh) * | 2018-11-06 | 2019-03-15 | 青岛古高生物科技有限公司 | 一种血红素-GroEL复合体及其制备方法和应用 |
| WO2021214501A1 (en) | 2020-04-22 | 2021-10-28 | Genima Innovations Marketing Gmbh | Antiviral decontamination in the runner suction hose or the antechamber of a breathing mask |
| CN115944714B (zh) * | 2022-10-20 | 2023-12-15 | 苏州大学 | 能够同时抗白细胞介素1和肿瘤坏死因子炎症的纳米材料及其制备方法与应用 |
| WO2024182789A1 (en) * | 2023-03-02 | 2024-09-06 | Reverb Therapeutics, Inc. | Cytokine-based therapies and methods, comprising mono- and bispecific non-blocking anti- cytokine antibody |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0467416A1 (en) * | 1983-09-01 | 1992-01-22 | Hybritech Incorporated | Antibody compositions of therapeutic agents having an extended serum half-life |
| SU1618761A1 (ru) | 1987-04-29 | 1991-01-07 | Институт Белка Ан Ссср | Способ получени пептидов и белков в бесклеточной системе трансл ции |
| ATE106250T1 (de) * | 1987-07-07 | 1994-06-15 | Hybrisens Ltd | Verwendung von antikörper-antigen-wechselwirkung zum schutz oder modulation der biologischen aktivität. |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| US5225540A (en) * | 1988-04-26 | 1993-07-06 | Du Pont Merck Pharmaceutical Company | Monoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life |
| JPH04504651A (ja) | 1988-11-18 | 1992-08-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 自然に存在しないアミノ酸をタンパク質に部位特異的に導入する方法 |
| SU1705302A1 (ru) | 1988-12-22 | 1992-01-15 | Институт Белка Ан Ссср | Способ препаративной экспрессии генов в бесклеточной системе сопр женной транскрипции/трансл ции |
| ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
| DE69029744T2 (de) | 1989-07-31 | 1997-07-10 | Inst Of Protein Research Russi | Verfahren zur herstellung von polypeptiden in einem zellfreien system |
| US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| CA2067194C (en) | 1989-10-05 | 2003-03-18 | Glenn Kawasaki | Cell-free synthesis and isolation of novel genes and polypeptides |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992002536A1 (en) | 1990-08-02 | 1992-02-20 | The Regents Of The University Of Colorado | Systematic polypeptide evolution by reverse translation |
| WO1992005258A1 (en) | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encoding barley enzyme |
| AU1435492A (en) | 1991-02-21 | 1992-09-15 | Gilead Sciences, Inc. | Aptamer specific for biomolecules and method of making |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| ATE427968T1 (de) | 1992-08-21 | 2009-04-15 | Univ Bruxelles | Immunoglobuline ohne leichtkette |
| AU8124694A (en) | 1993-10-29 | 1995-05-22 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| GB9416721D0 (en) | 1994-08-18 | 1994-10-12 | Short Brothers Plc | A bias yarn assembly forming device |
| AU703091B2 (en) * | 1995-08-04 | 1999-03-18 | Lek Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Monoclonal antibodies against soluble TNF-alpha receptors p55 and p75 as well as against TNF-alpha and its analogues |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| US5837251A (en) | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
| CA2258518C (en) | 1996-06-27 | 2011-11-22 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Recognition molecules interacting specifically with the active site or cleft of a target molecule |
| WO1998058965A2 (en) | 1997-06-20 | 1998-12-30 | Innogenetics N.V. | B7-binding molecules for treating immune diseases |
| WO1999002671A1 (en) | 1997-07-07 | 1999-01-21 | Medical Research Council | In vitro sorting method |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| EP1027439B1 (en) | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Multivalent antigen-binding proteins |
| BR9907241A (pt) | 1998-01-26 | 2000-10-17 | Unilever Nv | Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo |
| EP1002861A1 (en) | 1998-10-26 | 2000-05-24 | Unilever Plc | Antigen-binding proteins comprising a linker which confers restricted conformational flexibility |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| GB9900298D0 (en) | 1999-01-07 | 1999-02-24 | Medical Res Council | Optical sorting method |
| ATE276359T1 (de) | 1999-01-19 | 2004-10-15 | Unilever Nv | Verfahren zur herstellung von antikörperfragmenten |
| AU4484400A (en) | 1999-04-23 | 2000-11-10 | University Of Washington | Prostate-specific polynucleotides, polypeptides and their methods of use |
| CA2372198A1 (en) | 1999-05-14 | 2000-11-23 | Medical Research Council | Protein scaffold and its use to multimerise monomeric polypeptides |
| EP1242460B1 (en) | 1999-11-29 | 2006-10-18 | Unilever Plc | Immobilisation of proteins using a polypeptide segment |
| WO2001058953A2 (en) * | 2000-02-11 | 2001-08-16 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
| ATE428733T1 (de) | 2000-03-14 | 2009-05-15 | Unilever Nv | Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| EP1399484B1 (en) | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
| US6608742B2 (en) | 2001-07-06 | 2003-08-19 | Schweitzer Engineering Laboratories, Inc. | Voltage and current source selection system for use in the protection, automation and control of an electric power system |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| DE10160133A1 (de) | 2001-12-07 | 2003-06-26 | Transmit Technologietransfer | Verwendung von koagulationsaktivem Antithrombin III zur Therapie von Angiogenese-abhängigen Erkrankungen |
| WO2003053531A1 (en) | 2001-12-11 | 2003-07-03 | Majorem Ltd. | Massive multiplayer real-time persistant network game engine |
| US20080108560A1 (en) | 2002-03-05 | 2008-05-08 | Eli Lilly And Company | Heterologous G-Csf Fusion Proteins |
| JP2006512050A (ja) * | 2002-06-21 | 2006-04-13 | ダイアックス、コープ | 血清タンパク質結合標的特異的リガンドとその同定方法 |
| DE60305919T2 (de) * | 2002-06-28 | 2007-01-18 | Domantis Limited, Cambridge | Dual-specifische liganden mit erhöhter halbwertszeit |
| US20060002935A1 (en) * | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| AU2003251238A1 (en) | 2002-08-07 | 2004-02-25 | Umc Utrecht Holding B.V. | Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| US6683132B1 (en) | 2002-12-19 | 2004-01-27 | Eastman Chemical Company | Self-crosslinking aqueous acetoacetate-functionalized sulfonated alkyd systems |
| EP1578801A2 (en) * | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| JP2006517789A (ja) | 2003-01-10 | 2006-08-03 | アブリンクス エン．ヴェー． | 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用 |
| CA2525120C (en) | 2003-05-14 | 2013-04-30 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
| CA2529819A1 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Pegylated single domain antibodies |
| WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| EP2251357A1 (en) | 2003-11-07 | 2010-11-17 | Ablynx N.V. | Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor |
| EP1729795B1 (en) | 2004-02-09 | 2016-02-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2561732A1 (en) * | 2004-03-30 | 2005-10-13 | Takeda Pharmaceutical Company Limited | Antibody drug |
-
2005
- 2005-10-07 CN CN200910246166A patent/CN101724071A/zh active Pending
- 2005-10-07 KR KR1020077010453A patent/KR20070084069A/ko not_active Ceased
- 2005-10-07 RU RU2007112509/10A patent/RU2401842C2/ru not_active IP Right Cessation
- 2005-11-10 AU AU2005303584A patent/AU2005303584A1/en not_active Abandoned
- 2005-11-10 JP JP2007540709A patent/JP2008519813A/ja active Pending
- 2005-11-10 CN CNA2005800461844A patent/CN101098712A/zh active Pending
- 2005-11-10 BR BRPI0517569-0A patent/BRPI0517569A/pt not_active IP Right Cessation
- 2005-11-10 WO PCT/GB2005/004319 patent/WO2006051288A2/en not_active Ceased
- 2005-11-10 RU RU2007117196/13A patent/RU2007117196A/ru not_active Application Discontinuation
- 2005-11-10 EP EP11161978A patent/EP2420251A3/en not_active Withdrawn
- 2005-11-10 EP EP05801585A patent/EP1814584A2/en not_active Ceased
- 2005-11-10 CA CA002587206A patent/CA2587206A1/en not_active Abandoned
- 2005-11-10 KR KR1020077012946A patent/KR20070089930A/ko not_active Withdrawn
-
2007
- 2007-04-03 NO NO20071788A patent/NO20071788L/no not_active Application Discontinuation
- 2007-05-07 MA MA29876A patent/MA29427B1/fr unknown
- 2007-05-16 NO NO20072475A patent/NO20072475L/no not_active Application Discontinuation
- 2007-06-06 MA MA29969A patent/MA29221B1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008519813A5 (enExample) | ||
| RU2007117196A (ru) | Лиганды, которые активируют эндогенные соединения | |
| JP2009519011A5 (enExample) | ||
| JP2020510662A5 (enExample) | ||
| JP2009517069A5 (enExample) | ||
| JP2016537340A5 (enExample) | ||
| JP2023071996A (ja) | 多剤抗体薬物コンジュゲート | |
| CN106029083B (zh) | 亲水性抗体-药物偶联物 | |
| US10182984B2 (en) | Targeted interferons demonstrate potent apoptotic and anti-tumor activities | |
| JP2022105640A (ja) | 四級化チューブリシン化合物の複合体 | |
| JP2009518025A5 (enExample) | ||
| US8580267B2 (en) | Immunocytokines for tumour therapy with chemotherapeutic agents | |
| EP2233156B1 (en) | Use of aprotinin polypeptides as carriers in pharmaceutical conjugates | |
| KR20210006362A (ko) | 캄토테신 펩타이드 접합체들 | |
| JP2008521870A5 (enExample) | ||
| JP2010500360A5 (enExample) | ||
| EP3007689B1 (en) | Non-selective kinase inhibitors | |
| US20160115239A1 (en) | Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities | |
| JP2012067099A5 (enExample) | ||
| RU2411957C2 (ru) | Способы лечения респираторного заболевания с применением антагонистов рецептора интерлейкина-1 типа 1 | |
| JP2009506790A5 (enExample) | ||
| RU2014101207A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| CA3173919A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer | |
| JPWO2022020105A5 (enExample) | ||
| JP2021513990A (ja) | 疎水性アウリスタチンｆ化合物およびそのコンジュゲート |